Ifosfamide
drugOn this page
Also known as IfexIfosfamidaIsocyclophosphamideIsophosphamideIfsofamideMitoxanaMJF 9325MJF-9325NSC-109724Z-4942Z4942SID11112546SID56463644SID301170SID144213092SID170464854SID144209013SID144204090SID174007357
Summary
Ifosfamide (CHEMBL1024) is an approved small-molecule antineoplastic agent (ATC L01AA06); indicated across 76 conditions including neoplasm and testicular cancer.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: L01AA06
- Indications: 76 conditions
- Clinical trials: 362
- Chemistry: 261.08 Da · C7H15Cl2N2O2P
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1024 |
| Name | Ifosfamide |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 3690 |
| ChEBI | CHEBI:5864 |
| ATC | L01AA06 |
| Molecular formula | C7H15Cl2N2O2P |
| Molecular weight | 261.08 |
| InChIKey | HOMGKSMUEGBAAB-UHFFFAOYSA-N |
SMILES: C1CN(P(=O)(OC1)NCCCl)CCCl
IUPAC name: N,3-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
ChEBI definition: The simplest member of the class of ifosfamides that is 1,3,2-oxazaphosphinan-2-amine 2-oxide substituted by 2-chloroethyl groups on both the nitrogen atoms respectively. It is a nitrogen mustard alkylating agent used in the treatment of advanced breast cancer.
Pharmacological roles (ChEBI): antineoplastic agent, immunosuppressive agent, alkylating agent.
Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.
Also known as: Ifex, Ifosfamida, Ifosfamide, Isocyclophosphamide, Isophosphamide, Ifsofamide, Mitoxana, MJF 9325, MJF-9325, NSC-109724, Z-4942, Z4942
Parent form; salt/anhydrous children: CHEMBL342466
Patent coverage: 33,835 distinct patent families (139,212 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prelamin-A/C, Beta-lactamase, Menin/Histone-lysine N-methyltransferase MLL, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| LMNA | 7.25 | Potency | 56.2 | nM | CHEMBL_ACT_3652624 |
| MEN1 | 5.55 | Potency | 2818 | nM | CHEMBL_ACT_4569805 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
76 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| testicular cancer | 4 | MONDO:0005447 | EFO:0004281 |
| osteosarcoma | 3 | MONDO:0009807 | EFO:0000637 |
| sarcoma | 3 | MONDO:0005089 | EFO:0000691 |
| neoplasm of mature B-cells | 3 | MONDO:0004949 | EFO:0000096 |
| Ewing sarcoma | 3 | MONDO:0012817 | EFO:0000174 |
| Hodgkins lymphoma | 3 | MONDO:0004952 | EFO:0000183 |
| acute lymphoblastic leukemia | 3 | MONDO:0004967 | EFO:0000220 |
| carcinoma | 3 | MONDO:0004993 | EFO:0000313 |
| diffuse large B-cell lymphoma | 3 | MONDO:0018905 | EFO:0000403 |
| germ cell tumor | 3 | MONDO:0005040 | EFO:0000514 |
| leukemia | 3 | MONDO:0005059 | EFO:0000565 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| neuroblastoma | 3 | MONDO:0005072 | EFO:0000621 |
| small cell lung carcinoma | 3 | MONDO:0008433 | EFO:0000702 |
| rhabdomyosarcoma | 3 | MONDO:0005212 | EFO:0002918 |
| non-small cell lung carcinoma | 3 | MONDO:0005233 | EFO:0003060 |
| non-Hodgkin lymphoma | 3 | MONDO:0018908 | EFO:0005952 |
| soft tissue sarcoma | 3 | MONDO:0018078 | EFO:1001968 |
| peripheral T-cell lymphoma, not otherwise specified | 3 | MONDO:0004964 | EFO:0000211 |
| fallopian tube carcinoma | 3 | MONDO:0006206 | EFO:1000251 |
| uterine carcinosarcoma | 3 | MONDO:0006485 | EFO:1000613 |
| T-cell acute lymphoblastic leukemia | 3 | MONDO:0004963 | EFO:0000209 |
| adrenal gland pheochromocytoma | 3 | MONDO:0004974 | EFO:0000239 |
| mediastinal cancer | 3 | MONDO:0005843 | EFO:0007362 |
| central nervous system neoplasm | 3 | MONDO:0006130 | EFO:1000158 |
| fallopian tube neoplasm | 3 | MONDO:0021092 | MONDO:0002158 |
| kidney cancer | 3 | MONDO:0002367 | MONDO:0002367 |
| teratoma | 3 | MONDO:0002601 | MONDO:0002601 |
| ovarian cancer | 3 | MONDO:0008170 | MONDO:0008170 |
| lung neoplasm | 3 | MONDO:0021117 | MONDO:0008903 |
| endometrium neoplasm | 3 | MONDO:0021251 | MONDO:0011962 |
| follicular lymphoma | 3 | MONDO:0018906 | MONDO:0018906 |
| leiomyosarcoma | 3 | MONDO:0005058 | EFO:0000564 |
| liposarcoma | 3 | MONDO:0005060 | EFO:0000569 |
| malignant peripheral nerve sheath tumor | 3 | MONDO:0017827 | EFO:0000760 |
| synovial sarcoma | 3 | MONDO:0010434 | EFO:0001376 |
| histiocytoma | 3 | MONDO:0005509 | EFO:0005561 |
| alveolar soft part sarcoma | 3 | MONDO:0011655 | EFO:0007143 |
| fibrosarcoma | 3 | MONDO:0005164 | MONDO:0002678 |
| dermatofibrosarcoma protuberans | 3 | MONDO:0011934 | MONDO:0011934 |
| angiosarcoma | 3 | MONDO:0016982 | MONDO:0003022 |
| acute myeloid leukemia | 2 | MONDO:0018874 | EFO:0000222 |
| alveolar rhabdomyosarcoma | 2 | MONDO:0009994 | EFO:0000248 |
| Burkitt lymphoma | 2 | MONDO:0007243 | EFO:0000309 |
| embryonal rhabdomyosarcoma | 2 | MONDO:0009993 | EFO:0000437 |
| exocrine pancreatic carcinoma | 2 | MONDO:0005192 | EFO:0002618 |
| anaplastic large cell lymphoma | 2 | MONDO:0020325 | EFO:0003032 |
| nasopharyngeal neoplasm | 2 | MONDO:0005375 | EFO:0004252 |
| mantle cell lymphoma | 2 | MONDO:0018876 | EFO:1001469 |
| penile neoplasm | 2 | MONDO:0006895 | MONDO:0001325 |
| peritoneal neoplasm | 2 | MONDO:0006901 | MONDO:0002087 |
| uterine cancer | 2 | MONDO:0002715 | MONDO:0002715 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| Wilms tumor | 2 | MONDO:0006058 | MONDO:0019004 |
| B-cell non-Hodgkin lymphoma | 2 | MONDO:0015759 | EFO:1001938 |
| myelodysplastic syndrome | 1 | MONDO:0018881 | EFO:0000198 |
| plasma cell myeloma | 1 | MONDO:0009693 | EFO:0001378 |
| myeloproliferative neoplasm | 1 | MONDO:0020076 | EFO:0002428 |
| plasma cell neoplasm | 1 | MONDO:0004959 | EFO:0000200 |
16 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 362.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 167 |
| PHASE3 | 82 |
| PHASE1/PHASE2 | 37 |
| PHASE1 | 29 |
| Not specified | 25 |
| PHASE4 | 11 |
| EARLY_PHASE1 | 6 |
| PHASE2/PHASE3 | 5 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05518383 | PHASE4 | RECRUITING | B-cell Mature Non-Hodgkin’s Lymphoma Treatment Protocol in Children and Adolescents 2021 |
| NCT05844813 | PHASE4 | ENROLLING_BY_INVITATION | Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma |
| NCT00199056 | PHASE4 | COMPLETED | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) |
| NCT00199069 | PHASE4 | COMPLETED | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) |
| NCT00199082 | PHASE4 | COMPLETED | Newly Diagnosed Mature B-ALL, Burkitt’s Lymphoma and Other High-grade Lymphoma in Adults |
| NCT00199095 | PHASE4 | COMPLETED | Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia |
| NCT01424839 | PHASE4 | UNKNOWN | Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors |
| NCT01501136 | PHASE4 | UNKNOWN | Treatment of Natural Killer/T Cell Lymphoma-I/II |
| NCT01746992 | PHASE4 | UNKNOWN | CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma |
| NCT03071822 | PHASE4 | UNKNOWN | Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas |
| NCT03514381 | PHASE4 | COMPLETED | Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma |
| NCT00470223 | PHASE3 | ACTIVE_NOT_RECRUITING | Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma |
| NCT02112916 | PHASE3 | ACTIVE_NOT_RECRUITING | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma |
| NCT02180867 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery |
| NCT02305654 | PHASE3 | RECRUITING | International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) |
| NCT02306161 | PHASE3 | ACTIVE_NOT_RECRUITING | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma |
| NCT02375204 | PHASE3 | ACTIVE_NOT_RECRUITING | Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors |
| NCT02845882 | PHASE3 | ACTIVE_NOT_RECRUITING | LBL-2016 for Children or Adolescents in China |
| NCT03007147 | PHASE3 | ACTIVE_NOT_RECRUITING | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
| NCT03206671 | PHASE3 | ACTIVE_NOT_RECRUITING | Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents |
| NCT03643276 | PHASE3 | RECRUITING | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 |
| NCT04043494 | PHASE3 | RECRUITING | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma |
| NCT04221035 | PHASE3 | RECRUITING | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) |
| NCT04833114 | PHASE3 | ACTIVE_NOT_RECRUITING | Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) |
| NCT05681260 | PHASE3 | RECRUITING | Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) |
| NCT05991388 | PHASE2/PHASE3 | RECRUITING | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma |
| NCT06230224 | PHASE3 | ACTIVE_NOT_RECRUITING | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma |
| NCT06647953 | PHASE3 | RECRUITING | Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma |
| NCT06792253 | PHASE3 | RECRUITING | Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| NCT06820957 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body |
| NCT00001300 | PHASE3 | COMPLETED | A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma |
| NCT00002516 | PHASE3 | UNKNOWN | Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing’s Sarcoma |
| NCT00002546 | PHASE3 | COMPLETED | Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus |
| NCT00002565 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin’s Lymphoma |
| NCT00002566 | PHASE3 | COMPLETED | Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors |
| NCT00002641 | PHASE3 | COMPLETED | Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma |
| NCT00002764 | PHASE3 | COMPLETED | Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma |
| NCT00002802 | PHASE3 | COMPLETED | Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma |
| NCT00002816 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia |
| NCT00002822 | PHASE3 | COMPLETED | Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 5 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: neoplasm, testicular cancer, osteosarcoma, sarcoma, neoplasm of mature B-cells, Ewing sarcoma, Hodgkins lymphoma, acute lymphoblastic leukemia, carcinoma, diffuse large B-cell lymphoma, germ cell tumor, leukemia, lymphoma, neuroblastoma, small cell lung carcinoma, rhabdomyosarcoma, non-small cell lung carcinoma, non-Hodgkin lymphoma, soft tissue sarcoma, peripheral T-cell lymphoma, not otherwise specified, fallopian tube carcinoma, uterine carcinosarcoma, T-cell acute lymphoblastic leukemia, adrenal gland pheochromocytoma, mediastinal cancer, central nervous system neoplasm, fallopian tube neoplasm, kidney cancer, teratoma, ovarian cancer, lung neoplasm, endometrium neoplasm, follicular lymphoma, leiomyosarcoma, liposarcoma, malignant peripheral nerve sheath tumor, synovial sarcoma, histiocytoma, alveolar soft part sarcoma, fibrosarcoma, dermatofibrosarcoma protuberans, angiosarcoma